Aspire Biopharma Holdings (ASBP) FCF Margin (2025 - 2026)

Aspire Biopharma Holdings (ASBP) posted quarterly FCF Margin of 10716.76% for Q1 2026, up 50.78% quarter-over-quarter from 21775.19% in Q4 2025.

Aspire Biopharma Holdings (ASBP) FCF Margin (2025 - 2026) Analysis & Trends

Aspire Biopharma Holdings (ASBP) has reported FCF Margin for 2 consecutive years, with 10716.76% the latest figure, recorded in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	139.57 Bn	131.72 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	86.71 Bn	78.72 Bn	3.93 Bn	13.35%
3	Argenx Se	65.44 Bn	60.25 Bn	1.37 Bn	-
4	Moderna	60.06 Bn	54.93 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.89 Bn	28.58 Bn	992.69 Mn	22.62%
7	BioNTech SE	28.11 Bn	9.72 Bn	668.28 Mn	41.07%
8	Insmed	27.59 Bn	26.43 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	70.82%
10	Aspire Biopharma Holdings	8.34 Mn	-3.83 Mn	-30,086.00	-3,352.68%

Download Data